Rapt Therapeutics, Inc. (RAPT)

Market Cap	713.54M
Revenue (ttm)	3.25M
Net Income (ttm)	-76.23M
Shares Out	29.66M
EPS (ttm)	-2.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	603,275
Open	23.87
Previous Close	23.87
Day's Range	23.28 - 25.14
52-Week Range	9.86 - 40.74
Beta	0.44
Analysts	Buy
Price Target	46.92 (+95.0%)
Earnings Date	Nov 8, 2022

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clini...

• Industry: Biotechnology
• IPO Date: Oct 31, 2019
• CEO: Brian Wong
• Employees: 88
• Stock Exchange: NASDAQ
• Ticker Symbol: RAPT

Full Company Profile

Financial Performance

In 2021, RAPT's revenue was $3.81 million, a decrease of -24.38% compared to the previous year's $5.04 million. Losses were -$69.20 million, 30.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price forecast is 46.92, which is an increase of 95.01% from the latest price.

Price Target

$46.92

(95.01% upside)

Analyst Consensus: Buy

Stock Forecasts